Use of cholinesterase inhibitors for treatment of Alzheimer disease

Ann Marie Hake, MD
Department of Neurology, Indiana University School of Medicine

Address: Ann Marie Hake, MD, Department of Neurology, Indiana University School of Medicine, 541 Clinical Drive, Room 583, Indianapolis, IN 46202; [email protected]

Dr. Hake has indicated she is on the speakers bureau of the Novartis, Pfizer, Eisai, and Janssen corporations.

This paper discusses therapies that are not yet approved by the US Food and Drug Administration for the use under discussion.

Ann Marie Hake, MD
Department of Neurology, Indiana University School of Medicine

Address: Ann Marie Hake, MD, Department of Neurology, Indiana University School of Medicine, 541 Clinical Drive, Room 583, Indianapolis, IN 46202; [email protected]

Dr. Hake has indicated she is on the speakers bureau of the Novartis, Pfizer, Eisai, and Janssen corporations.

This paper discusses therapies that are not yet approved by the US Food and Drug Administration for the use under discussion.

Ann Marie Hake, MD
Department of Neurology, Indiana University School of Medicine

Address: Ann Marie Hake, MD, Department of Neurology, Indiana University School of Medicine, 541 Clinical Drive, Room 583, Indianapolis, IN 46202; [email protected]

Dr. Hake has indicated she is on the speakers bureau of the Novartis, Pfizer, Eisai, and Janssen corporations.

This paper discusses therapies that are not yet approved by the US Food and Drug Administration for the use under discussion.